https://www.selleckchem.com/pr....oducts/isa-2011b.htm
Background There is increasing use of Phase I statistical designs to find a dose that causes rapidly emerging and particularly concerning severe or life-threatening toxicities (dose-limiting toxicities, DLTs) in a specified percent of patients most commonly 25%. While a convenient statistical framework, the foundation for selecting any specified target DLT rate, and its relevance to the recommended Phase II dose is generally lacking. Method We surveyed 78 medical oncologists, most (69%) with experience as a principal investigator on a
Like
Comment
Share
